Embodiments of the present disclosure pertain to methods of detecting hypoxemia in a subject by: (1) receiving a blood sample from the subject; (2) measuring the T.sub.2 relaxation time constant of the blood cell (e.g., blood cell pellet) of the blood sample (T.sub.2P value); and (3) correlating the measured T.sub.2P value to hypoxemia. In some embodiments, the methods of the present disclosure also include a step of correlating the measured T.sub.2P value to the subject's susceptibility to one or more hypoxemia-related conditions. Further embodiments of the present disclosure pertain to systems for detecting hypoxemia in a subject in accordance with the methods of the present disclosure.

Improved analyte detection system within a blood gas analyzer, the improved system comprising and/or consisting of at least one CO-oximetry system that is formed as an integrated, unitary structure(s) with an electrochemical sensor module, and methods of use related thereto.

Systems and methods are provided for determining the age of cellular hemoglobin in individual red blood cells in a blood sample by determining the percentage of HbA1c. In embodiments, a method includes measuring side scatter and fluorescence of the individual red blood cells and identifying immature red blood cells and mature red blood cells from the side scatter and fluorescence measurement. In embodiments, data collected includes the exact number of red blood cells, the fraction limits in fluorescence and side scatter units, the mean value of each fraction in fluorescence and side scatter units, the mean FL1 values per fraction in arbitrary units and the mean side scatter values per fraction in arbitrary units. In embodiments, a method also includes deriving a HbA1c content from the measured mean fluorescence of the individual red blood cells and determining the percentage of HbA1c from the HbA1c content and the hemoglobin content of the red blood cells.

A sample collection device for a fluid sample includes: a body including a capillary channel having a first end and a second end, wherein the first end is adapted to draw the fluid into the channel by capillary action; an air vent located in the vicinity of the second end and in fluid communication with the capillary channel; a barrier positioned within the capillary channel to prevent flow of the fluid by capillary action thereacross; and features on opposing sides of the body to form an axis of rotation, which is substantially perpendicular to the overall direction of the capillary channel from the first end to the second end. In a preferred embodiment, the sample collection device is adapted to rotate about the axis of rotation within a cartridge having a sample manipulation device to bring the first end into position with the sample manipulation device.

Methods and systems are presented for analyzing the blood of a living being. Equations are presented for volume-aware extension of the concept of Hematocrit. A method for calculating these volume-aware measures and using said measures to evaluate and guide possible treatments is described. A system comprising an automated analyzer and a processor and other components is described which can carry out said calculations. Methods of treatment for volume abnormalities are described which are guided by the volume-aware Hct measures. In one exemplary embodiment, a method of treatment for plasma volume excess using ultrafiltration is described. In another exemplary embodiment, a method of treatment for red cell volume excess using erythrocytapheresis is described.

A storage and monitoring device for red blood samples in storage for donation (blood bank) and research. Stored blood can be susceptible to degradation, most often from a phenomenon known as ice nucleation. Accurate detection and identification of relevant factors causing ice nucleation can determine healthy samples of stored blood, and identify storage factors that promote storage longevity. A photodetection approach directs an illumination source and photometer on opposed sides of a blood containing vessel for measuring an illuminance affected by hemoglobin released from ruptured cells. Hemoglobin released from ruptured cells reduces light passage though the sample to indicate unusable samples. An accelerometer and temperature sensor measure the physical and temperate factors correlating with the detected cell degradation to determine storage criteria for extending blood longevity.

A sample analyzer prepares a measurement sample from a blood sample or a body fluid sample which differs from the blood sample; measures the prepared measurement sample; obtains characteristic information representing characteristics of the components in the measurement sample; sets either a blood measurement mode for measuring the blood sample, or a body fluid measurement mode for measuring the body fluid sample as an operating mode; and measures the measurement sample prepared from the blood sample by executing operations in the blood measurement mode when the blood measurement mode has been set, and measuring the measurement sample prepared from the body fluid sample by executing operations in the body fluid measurement mode that differs from the operations in the blood measurement mode when the body fluid measurement mode has been set, is disclosed. A computer program product is also disclosed.

The present invention relates to the optical measurement of blood analytes, such as glycated hemoglobin (HbA1c) and serum albumin as a functional metric of mean blood glucose in the diagnosis of diabetic patients. Non-enhanced Raman spectroscopy is employed as the analytical method for quantitative detection of blood analytes. Using processing techniques, non-enzymatic glycosylation (glycation) of the analytes results in measurable and highly reproducible changes in the acquired spectral data, which enable the accurate measurements and classification of glycated and unglycated analytes.

The disclosure provides methods, kits, and devices for determining an amount of hemoglobin S and/or an amount of total hemoglobin, and optionally, expressing the amount of hemoglobin S as a percentage. Devices of the disclosure may be used as point-of-care diagnostic systems accessible for use to a layperson, i.e., an individual with minimal or no medical training or expertise.

Screening methods and devices for detecting and diagnosing hemoglobinopathies for sickle cell disease and related phenotypes. Lateral flow immunoassay devices for the detection of hemoglobinopathies. Methods for screening for hemoglobinopathies. Kits for the detection of a hemoglobinopathy in a sample. Immunogenic peptides for producing antibodies against hemoglobin variants.